Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment
- Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth
asserted
intake → increase → growth
Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments
- Operating cash flow of EUR 544 million; free cash flow of EUR 384 million
-
asserted
margin → adjust → million
Respironics reached agreement in principle with the US Department of Justice
asserted
Respironics → reach → Department
- Philips reiterates its full-year 2026 outlook
Roy Jakobs, CEO of Royal Philips:
“We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care.
asserted
We → reiterate → Health
Our innovations and productivity measures drove continued margin expansion across all business segments.
asserted
innovations → drive → segments
We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution.
asserted
We → execute → platforms
These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers.
asserted
platforms → demonstrate → customers
We look forward to showcasing our next innovations at RSNA later this month.
asserted
We → look → RSNA
We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall.
asserted
We → continue → recall
The Respironics agreement in principle with the US Department of Justice marks an important step in this process.
asserted
agreement → mark → process
Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions.
asserted
results → give → ambitions
As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people.
asserted
we → move → people
Group and segment performance
Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment.
asserted
intake → grow → Diagnosis
Comparable sales increased by 3%, driven by Personal Health and Connected Care.
Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation.
asserted
margin → increase → inflation
Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows.
asserted
flows → operate → earnings
Free cash flow increased to EUR 384 million.
asserted
flow → increase → million
Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2.
asserted
Growth → offset → Q2
Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.
asserted
margin → increase → inflation
Connected Care comparable sales increased by 5%, driven by growth in all businesses.
asserted
sales → increase → businesses
Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.
Personal Health comparable sales increased by 8%.
asserted
sales → increase → %
Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.
asserted
margin → increase → spend
Philips is accelerating innovation in image-guided therapy.
asserted
Philips → accelerate → therapy
In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds.
asserted
Philips → invest → funds
In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.
asserted
award → support → platform
The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.
asserted
project → coordinate → solutions
- Philips extended its monitoring partnership with one of the largest US health systems through 2034.
asserted
Philips → extend → 2034
The national agreement covers equipment and services, expands the use of Philips’ Capsule platform, and supports future technology needs.
asserted
agreement → cover → needs
- Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings.
asserted
Health → select → settings
This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.
asserted
Archive → support → care
- Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico’s largest public healthcare institution, IMSS.
asserted
Philips → support → institution
The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.
asserted
projects → bring → care
- Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China.
asserted
Philips → sign → China
The partnership will focus on clinical care, training, research and international collaboration, combining Philips’ diagnostic imaging and image-guided therapy capabilities with Asia Medical Group’s cardiovascular expertise.
asserted
partnership → focus → expertise
- Personal Health launched innovations across oral care, beauty and mother and child care.
asserted
Health → launch → care
These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent’s first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.
asserted
These → include → consumers
Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date.
asserted
initiatives → deliver → date
The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.
asserted
company → remain → program
Progress on Respironics-related legal proceedings
Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall.
asserted
Respironics → relate → recall
As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026.
asserted
Philips → record → 2026
The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.
asserted
payment → expect → 2027
…and 35 more, not listed.
The Aporia
